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Abstract 
 
Naturally occurring variation in gene copy number is increasingly recognized as a heritable 
source of susceptibility to genetically complex diseases. Here we report robust association 
between FCGR3B copy number and risk of SLE (P=1.4*10-5), microscopic polyangiitis 
(P=2.9*10-4), and in two independent cohorts of Wegener’s granulomatosis from the UK 
(P=3*10-3) and France (P=1.1*10-4). We did not observe this association in the organ 
specific Grave’s and Addison’s diseases. Our findings suggest that FCGR3B copy number 
plays a key role in the pathogenesis of systemic autoimmune diseases.  
 
Structural variation is now recognised as a rich source of genetic diversity in the human genome 
and during the past five years, thousands of common copy number variants (CNV) have been 
described1. Although the association of rare CNVs in single gene disorders and in mental 
retardation has been established2, the role of more common, transmissible CNVs in evolutionary 
selection and disease susceptibility is largely unknown. 
 
Analyses of the functional attributes of genes reported to show CNV have revealed enrichment 
for genetic determinants involved in immune responses, inflammation and drug detoxification3. 
We recently reported an association between low copy number of the FCGR3B gene and 
autoimmune glomerulonephritis in a sample of patients with systemic lupus erythematosus (SLE) 
from UK nuclear families4. Since Fc gamma receptors play a key role in the initiation and 
regulation of the humoral-induced inflammatory response5-7, we hypothesized that CNV in 
FCGR3B may confer susceptibility to a range of autoimmune disorders.  
 Gene copy number was estimated by quantitative real-time PCR assay as previously described4, 
additionally validated by semi-quantitative PCR (Supplementary Figure 1). Significance of the 
differences in FCGR3B copy number between cases and controls was estimated by 
nonparametric Mann-Whitney U-test and risk ratios were estimated by multivariate logistic 
regression models4. 
 
First, we confirmed and strengthened the association between glomerulonephritis in SLE and 
CNV at FCGR3B (Mann-Whitney U–test P = 1.4*10-8, 95% CI 0-2.9*10-5, Fig. 1a) in a larger 
sample including 161 SLE patients with glomerulonephritis from the UK and 312 independent 
controls from the UK 1958 birth cohort8. Compared with possession of two copies of FCGR3B, 
individuals possessing fewer than two copies had significantly higher risk of glomerulonephritis 
(odds ratio (OR) = 2.431, 95% CI 1.47-4.0, P = 1*10-3)(Table 1a). We then investigated the 
involvement of CNV at FCGR3B in the development of SLE with no known renal involvement 
in an expanded set of 375 unrelated cases from the UK. All phenotypes were defined according to 
ACR criteria9. We found a strong association (Mann-Whitney U-test, P = 1.4*10-5, 95% CI 0-
2.9*10-5, Fig. 1b; Table 1a) and increased risk for development of SLE with <2 FCGR3B copy 
number (OR = 2.2, 95% CI 1.13-3.40, P = 3*10-4) (Table 1a). However, no significant increased 
risk of acquiring glomerulonephritis was observed in SLE subjects who possessed <2 copy 
number at FCGR3B (OR = 1.093, 95% CI 0.735-1.625, P = 0.660).  These data suggest that CNV 
at FCGR3B is an independent risk factor for both SLE and glomerulonephritis. In our previous 
report4 we did not find a significant association with SLE using discordant sib pair analysis (P = 
0.083, n=187 sib-pairs), although we recognized that the shared genetic background in sib-pairs 
decreased the power to detect the genetic effect of FCGR3B copy number. Here we use a larger 
(n=312) and independent control population in the association analysis which provides higher 
power to detect independent association with SLE (P = 1.4*10-5) and glomerulonephritis (P = 
1.4*10-8). 
 
These findings led us to investigate whether FCGR3B may be a common susceptibility gene for 
other autoimmune diseases with or without glomerular involvement. We therefore studied 
ANCA-associated vasculitis, a systemic autoimmune disorder in which renal disease occurs 
commonly. Patients with ANCA-associated vasculitis typically present with one of two clinical 
syndromes – microscopic polyangiitis (MPA) or Wegener’s granulomatosis (WG); these two 
subtypes were considered separately. We also studied Grave’s disease (GD) and a uniform cohort 
of Addison (ADD) patients with adrenal failure, as examples of organ-specific autoimmune 
diseases with no renal involvement. 
 
In two independent cohorts of patients with WG, from the University of Birmingham (80 cases 
and 190 unrelated controls), and from the Necker Hospital in Paris (84 cases and 181 unrelated 
controls), we found association between low FCGR3B copy number and susceptibility to WG 
(Birmingham cohort, Mann-Whitney U-test, P = 3*10-3, 95% CI 2.5*10-3-3.1*10-3; Paris cohort, 
Mann-Whitney U-test, P = 1.1*10-4, 95% CI 4.5*10-5-1.7*10-4) (Fig. 1c, 1d). In a separate 
Birmingham cohort of patients with MPA (76 cases) compared to the 190 Birmingham controls, 
we found significant association between MPA and FCGR3B copy number (Mann-Whitney U-
test, P = 2.9*10-4, 95% CI 1.8*10-4-3.9*10-4, Fig. 1e). In contrast to the association of MPA and 
WG with FCGR3B copy number, no association was seen between FCGR3B and either Grave’s 
disease (429 cases from Birmingham, Mann-Whitney U-test, P = 0.65, 95% CI 0.64-0.65, Fig. 
1f) or Addison’s disease (74 cases vs. 179 controls from Newcastle, Mann-Whitney U-test, P = 
0.057, 95% CI 0.056-0.059, Fig. 1g). Logistic regression models indicated an increased risk of 
WG and MPA in patients carrying low FCGR3B copy number, with OR = 2.464 (95% CI 1.19-
5.1, P = 0.015) and OR = 2.561 (95% CI = 1.217-5.389, P = 0.013) respectively (Table 1a) but 
did not show significant increased risk with low copy number in the French WG cohort. Logistic 
regression showed no association between low FCGR3B copy number and both Grave’s and 
Addison’s disease (Table 1a). The genetic effect of high copy number in these populations is less 
clear. We observed a protective effect for WG in the French cohort (OR = 0.277, P = 0.002, 
Table 1a) and for development of glomerulonephritis in UK SLE cases (OR = 0.309, P = 0.01, 
data not shown), and an increased risk of disease in patients carrying >2 copies of FCGR3B in the 
ADD cohort (OR = 3.438, P = 0.014, Table 1a). 
 
A striking association was seen between frequency of zero FCGR3B copy number and 
development of autoimmunity in SLE, glomerulonephritis and ANCA associated vasculitis 
(Table 1b). Zero copy number, which suggests complete genomic absence of FCGR3B and 
likely total deficiency of FCGR3B protein10, was seen in 25 out of 1279 cases of autoimmunity 
but in only one of 862 healthy controls. This suggests that complete FCGR3B deficiency is a, 
newly defined, highly penetrant risk factor for development of systemic autoimmunity. However, 
we did not observe a significant correlation between possession of zero FCGR3B copy number 
and early age of onset in the autoimmune diseases considered in this study. 
 
These results show an association between low FCGR3B copy number and risk of development 
of both SLE and ANCA-associated vasculitis both of which are associated with systemic 
inflammation and commonly involve the glomerulus. In contrast we found no association with 
GD and ADD, both organ-specific autoimmune diseases, suggesting different mechanisms 
leading to autoimmunity in these disorders. FCGR3B is expressed by neutrophils and eosinophils. 
It plays an important role in tethering of neutrophils to immune complexes and may play a role in 
clearance of immune complexes11. We hypothesize that, in patients with SLE, reduced clearance 
of immune complexes predisposes to disease in glomeruli and at other sites. In ANCA-associated 
vasculitis Fc-receptor mediated activation of neutrophils leads to inflammation12,13 and it may 
appear paradoxical that low copy number of FCGR3B should be protective. However, recent 
work (Tsuboi N, JASN 2006; abstract# SA-FC063) in transgenic animals shows that human 
FCGR3B is not pro-inflammatory in glomerular inflammation whereas the other human 
neutrophil Fcgamma receptor FCGR2A is pro-inflammatory. We therefore speculate that the 
balance between expression of FCGR3B and FCGR2A on neutrophils determines their relative 
efficiency in immune complex removal and inflammatory activation and may explain the effect 
of low copy number of FCGR3B in both SLE and ANCA vasculitis. 
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Figure 1. Histograms showing the distribution of FCGR3B copy number in different 
groups of cases (filled columns) versus unaffected controls (open columns). a, lupus 
glomerulonephritis; b, systemic lupus erythematosus; c, UK Wegener’s granulomatosis; 
d, French Wegener’s granulomatosis; e, microscopic polyangiitis; f Grave’s disease, g 
Addison’s disease. Nonparametric Mann-Whitney U-test was applied to assess 
association with gene copy number at FCGR3B; 2-tailed P-values for significance were 
estimated by 100,000 Monte Carlo simulations. n, number of subjects in each group.  
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Table 1. a, Logistic regression results and risk estimates for lupus glomerulonephritis, 
SLE, MPA, WG in UK and French population samples, and GD. OR, odds ratio, risk of 
acquiring disease relative to the population-specific median (CNV = 2). An odds ratio >1 
indicates a detrimental effect of FCGR3B copy number, and <1 indicates a protective 
effect of FCGR3B copy number. In all logistic regression models gender and age were 
included as covariates. CI, confidence interval; P-value, level of significance of OR. b, 
Clinical features of affected individuals carrying zero FCGR3B copy number. nk, not 
known. 
 
 
 
Autoimmune 
disease 
Cases/ 
controls 
Copy number 
categories 
OR 95% CI P-value 
< 2 2.431 1.467-4.028 0.001 Lupus 
Glomerulonephritis 
152/312 
> 2 0.406 0.153-1.075 0.07 
 
     
< 2 2.207 1.132-3.400 0.0003 
SLE 359/312 
> 2 1.127 0.634-2.001 0.684 
 
     
< 2 2.464 1.190-5.100 0.015 
WG (UK) 80/188 
> 2 0.756 0.319-1.792 0.525 
 
     
< 2 1.577 0.762-3.267 0.220 
WG (France) 77/181 
> 2 0.277 0.123-0.624 0.002 
 
     
< 2 2.561 1.217-5.389 0.013 
MPA 76/188 
> 2 0.525 0.194-1.421 0.204 
 
     
< 2 0.874 0.512-1.491 0.621 
GD 278/188 
> 2 0.883 0.556-1.404 0.599 
 
     
< 2 0.673 0.316-1.433 0.304 
ADD 71/185 
> 2 3.438 1.283-9.219 0.014 
 
 
 
a 
  Gender Clinical Diagnosis 
Current 
Age 
Age at 
Diagnosis 
Renal 
Involvement 
Cases 
     
 Male Lupus Glomerulonephritis 53 nk + 
 Male Lupus Glomerulonephritis 36 28 + 
 Female Lupus Glomerulonephritis nk nk + 
 Female Lupus Glomerulonephritis 40 34 + 
 Female Lupus Glomerulonephritis 21 nk + 
 Female Lupus Glomerulonephritis 27 nk + 
 Female Lupus Glomerulonephritis 31 27 + 
 Male SLE 32 18 - 
 Female SLE 39 nk - 
 Female SLE 36 nk - 
 Female SLE 47 nk - 
 Female SLE 40 34 - 
 Female SLE 20 nk - 
 Female SLE 54 nk - 
 Female SLE 51 nk - 
 Male SLE 22 nk - 
 Female SLE 28 19 - 
 Male SLE 52 44 - 
 Female SLE 60 nk - 
 Female SLE 53 nk - 
 Female SLE 38 20 - 
 Female MPA 68 67 + 
 Female WG 84 nk nk 
 Male GD 60 51 - 
 Female GD 62 49 - 
Controls 
     
 Female  48   
b 
Supplementary Figure 1.  Copy number variation of FCGR3B gene was confirmed by semi-quantitative PCR using human genomic 
DNA from ANCA vasculitis patients in which copy number has been determined by quantitative PCR. (a)The top bands indicate 0, 1, 
2 and 4 copies of FCGR3B gene; bottom bands show 2 copies of FOXP2 control gene. FCGR3B gene amplification products were 
sequence verified. (b) Quantification of amplicons by densitometry. After normalization to FOXP2 band intensities, the ratios of 
intensities between subjects with different FCGR3B copy number (CN) were calculated. Ratios were as follows: 2.5 for CN 2 vs. CN 
1; 3.8 for CN 4 vs. CN 1. 
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